Exact Sciences Schedules Announcement and Call for Top-Line Results of DeeP-C Clinical Trial

Wed, 04/17/2013 - 6:45pm
The Associated Press

MADISON, Wis.--(BUSINESS WIRE)--Apr 17, 2013--Exact Sciences Corp. (Nasdaq: EXAS) will announce the preliminary, top-line results of its DeeP-C pivotal clinical trial on Thursday, April 18, 2013, prior to the market open. The company will host a webcast and conference call to discuss the results that morning at 7:30 ET.

The DeeP-C study, one of the largest of its kind, included more than 10,000 patients and evaluated the use of the company’s stool-based DNA screening test for the early detection of colorectal cancer. It was conducted among a population of patients between the ages of 50 and 84 who were at average risk of colorectal cancer. The results of the DeeP-C trial are expected to form the basis of the company’s submission to the U.S. Food and Drug Administration for pre-market approval (PMA) of the convenient, non-invasive test.

DeeP-C Top-line Results Webcast & Conference Call Details An archive of the webcast will be available at A replay of the conference call will be available by calling 855-859-2056 domestically or 404-537-3406 internationally. The access code for the replay is 45786044. The webcast, conference call and replay are open to all interested parties.

About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on the early detection of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. For more information, please visit the company's website at


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.